Navigation Links
Beaumont Health System launches research trial of bioresorbable heart scaffold
Date:7/29/2013

Beaumont Health System has joined a multicenter, international research study of a new temporary heart device that helps keep an artery open following angioplasty, then is broken down and absorbed by the body.

The research will compare the effectiveness of the new "disappearing" device, the AbsorbTM Bioresorbable Vascular Scaffold made by health care company Abbott, with drug-eluting, metal stents that are commonly placed in heart arteries as a permanent implant. Absorb is referred to as a scaffold to indicate it is temporary in nature, unlike a permanent metallic stent. It is made of polylactide, a material commonly used in medical implants such as dissolving sutures. Coronary artery stents were approved for use in the United States in 1994. Similar to a mesh tube, stents prop open a heart artery after a blockage is cleared with a procedure called angioplasty.

In angioplasty, a doctor threads a catheter, or hollow tube, into the arteries of the heart through a small incision in the groin or wrist, with a tiny balloon at its tip that, once inflated, pushes a blockage against the artery wall to open the artery and improve blood flow to the heart. Angioplasty is often followed by insertion of a stent coated with medication, called a drug-eluting stent, at the site of the blockage to keep the vessel open and prevent renarrowing. Metallic stents are a permanent implant in the wall of the artery.

"Stents have revolutionized the treatment of heart blockages by helping many patients to avoid having repeat angioplasty procedures and in some cases open-heart surgery," says Amr Abbas, M.D., Beaumont's director of interventional cardiology research and the study's principal investigator. "This new bioabsorbable vascular scaffold is the latest technique in heart treatment in interventional cardiology."

Research has shown that the support of a coronary stent is only needed for a few months after implantation while the artery wall is healing. Although researchers hoped to create a temporary scaffold that dissolved after doing its job, there were many scientific challenges. A decade ago, scientists at Abbott started development of Absorb and now Abbott is the first company in the world to begin testing a bioresorbable vascular scaffold in patients in the United States.

The Absorb BVS is available in Europe, Middle East and parts of Asia. It is an investigational device not available for sale in the U.S.

ABSORB III will enroll approximately 2,250 patients, the majority in the U.S.


'/>"/>

Contact: Angela Blazevski
angela.blazevski@beaumont.edu
248-551-0445
Beaumont Health System
Source:Eurekalert

Related medicine news :

1. Beaumont Study: Nerve Stimulation Helps with Overactive Bladder
2. Beaumont Health System Recognized as an American Heart Association Fit-Friendly Worksite
3. Beaumont Cardiologist Kavitha Chinnaiyan, M.D., Receives Excellence in Research Award
4. Beaumont cardiologist Kavitha Chinnaiyan, M.D., receives excellence in research award
5. Beaumont receives national green award
6. Beaumont recipient of 2013 Dove Award from the Arc of Oakland County
7. Beaumont Childrens Hospital pediatrician inducted into Legends of Neonatology Hall of Fame
8. Beaumont doctors call for training to reduce sudden cardiac arrest fatalities in schools
9. Gulfside Dental Visits First Steps Daycare in Beaumont, TX
10. Gulfside Dental Celebrating Seniors Mardi Gras at Beaumont Civic Center
11. Gulfside Dental Now Offers LUMINEERS in Beaumont, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short ... has already been receiving positive feedback from customers trying the product for the first ... Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes ...
(Date:9/20/2017)... ... 2017 , ... Five consumer packaged goods (CPG) products were selected by the ... Nopavera Plus was named to the short list in the Specialty Supplements ... during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay Bay Resort ...
(Date:9/20/2017)... ... September 20, 2017 , ... Medicare doesn’t ... risk of price gouging for their prescription drugs, according to a new comparison ... isn’t negotiating on our behalf, there’s no consistency in drug pricing among drug ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... poor, the new feel good program from Leany Greeny delivers positive results in ... can rejuvenate overall health and kickstart the metabolism. Fitting seamlessly into hectic work ...
(Date:9/20/2017)... ... September 20, 2017 , ... “RECYCLED ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION” is the creation of published author, ... field of addiction and homeless services, including more than a decade of addiction ...
Breaking Medicine News(10 mins):
(Date:9/1/2017)... Mass. , Sept. 1, 2017 ... HealthCare Solutions, Inc , highlights opportunities for growth in ... Journal report that Marlin Equity is seeking a buyer ... an annual award-winning 22-year-old healthcare solutions Value Added Reseller ... "As the healthcare ...
(Date:9/1/2017)... Sept. 1, 2017  Bayer will present the latest research ... for Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... new preclinical and clinical data on Bayer,s marketed portfolio and ... projects. "We value ... in cancer research at ESMO," said Carsten Brunn , ...
(Date:8/29/2017)... ivWatch, LLC, the leading provider of continuous monitoring devices ... been awarded an Innovative Technology contract from Vizient, Inc., the largest ... ... the early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ivWatch ...
Breaking Medicine Technology: